439811-37-7

Basic information

• Product Name: 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE
• Synonyms: 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE;tert-butyl 4-(4-broMobenzoyl)piperidine-1-carboxylate;tert-butyl 4-[(4-broMophenyl)carbonyl]piperidine-1-carboxylate
• CAS NO: 439811-37-7
• Molecular Formula: C₁₇H₂₂BrNO₃
• Molecular Weight: 368.27
• EINECS: 200-589-5
• Mol File: 439811-37-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 452.3 °C at 760 mmHg
• Flash Point: 227.3 °C
• Appearance: /
• Density: 1.325 g/cm³
• Vapor Pressure: 2.27E-08mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: 2-8°C
• PKA: -2.47±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE(439811-37-7)
• EPA Substance Registry System: 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE(439811-37-7)

Safety Data

• Hazardous Substances Data: 439811-37-7(Hazardous Substances Data)

Usage

General Description

1-BOC-4-(4-Bromo-Benzoyl)-Piperidine is a chemical compound that consists of a piperidine ring with a BOC (tert-butoxycarbonyl) protecting group at the nitrogen, and a 4-(4-bromo-benzoyl) substituent. 1-BOC-4-(4-BROMO-BENZOYL)-PIPERIDINE is commonly used as an intermediate in the synthesis of pharmaceutical drugs and organic compounds. The BOC protecting group makes the piperidine nitrogen less reactive, allowing for selective reactions at other functional groups in the molecule. The presence of the 4-(4-bromo-benzoyl) group provides a site for further chemical modification and functionalization. Overall, 1-BOC-4-(4-Bromo-Benzoyl)-Piperidine is a versatile building block in organic chemistry, with potential applications in drug discovery and synthesis.

InChI:InChI=1/C17H22BrNO3/c1-17(2,3)22-16(21)19-10-8-13(9-11-19)15(20)12-4-6-14(18)7-5-12/h4-7,13H,8-11H2,1-3H3

Upstream product

• 203186-01-0 1-[4-(4-bromobenzoyl)piperidin-1-yl]-2,2,2-trifluoroethanone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1046478-89-0 tert-butyl 4-(p-tolylsulfonylhydrazono)-piperidine-1-carboxylate 
• 1122-91-4 4-bromo-benzaldehyde 
• 746550-66-3 (4-bromo-phenyl)-piperidin-4-yl-methanone 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 903899-02-5 4-[(4-bromo-phenyl)-(5,6-dichloro-1H-benzoimidazol-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 903899-03-6 4-[(4-bromo-phenyl)-(5,6-difluoro-1H-benzoimidazol-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-55-6 C₃₀H₄₀BrCl₂N₃O₄Si 
• 1609483-42-2 4-(4-methoxycarbonylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester 
• 847614-80-6 4-[(4-bromophenyl)hydroxymethyl]piperidine-1-carboxylic acid t-butyl ester 
• 847614-90-8 4-[[(6-chloro-5-fluoro-1H-benzoimidazol-2-ylmethyl)-amino]-(3'-cyano-biphenyl-4-yl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

1,4-DICARBONYL-PIPERIDYL DERIVATIVES

Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Preparation of unsymmetrical ketones from tosylhydrazones and aromatic aldehydes via formyl C-H bond insertion

Preparation of ketones by insertion of diazo compounds into the formyl C-H bond of an aldehyde is an attractive procedure, but use of structurally diverse diazo compounds is hampered by preparation and safety issues. A convenient procedure for the synthesis of unsymmetrical ketones from bench-stable tosylhydrazones and aryl aldehydes is reported. The procedure can be performed in one pot from the parent carbonyl compound and needs only a base, with no additional promoters being required.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases